After publication of the results of the National Institute of Neurological Disorders and Stroke study, the application of intravenous thrombolysis for ischemic stroke was launched and has now been in use for more than 10 years. The approval of this drug represented only the first step of the therapeutic approach to this pathology. Despite proven efficacy, concerns remain regarding the safety of recombinant tissue-type plasminogen activator for acute ischemic stroke used in routine clinical practice. As a result, a small proportion of patients are currently treated with thrombolytic drugs. Several factors explain this situation: a limited therapeutic window, insufficient public knowledge of the warning signs for stroke, the small number of centers able to administer thrombolysis on a 24-hour basis and an excessive fear of hemorrhagic complications. The aim of this review is to explore the clinical efficacy of treatment with alteplase and consider the hemorrhagic risks

Marcheselli, Simona

Micieli, Giuseppe

Tosi, Piera Angela

English

PubMed

Giuseppe Micieli, Simona Marcheselli, Piera Angela TosiNeurology and Stroke Unit, IRCCS Istituto Clinico Humanitas, Rozzano (MI), italyAbstract: After publication of the results of the National Institute of Neurological Disorders and Stroke study, the application of intravenous thrombolysis for ischemic stroke was launched and has now been in use for more than 10 years. The approval of this drug represented only the first step of the therapeutic approach to this pathology. Despite proven efficacy, concerns remain regarding the safety of recombinant tissue-type plasminogen activator for acute ischemic stroke used in routine clinical practice. As a result, a small proportion of patients are currently treated with thrombolytic drugs. Several factors explain this situation: a limited therapeutic window, insufficient public knowledge of the warning signs for stroke, the small number of centers able to administer thrombolysis on a 24-hour basis and an excessive fear of hemorrhagic complications. The aim of this review is to explore the clinical efficacy of treatment with alteplase and consider the hemorrhagic risks.Keywords: rt-PA, acute ischemic stroke, intracranial hemorrhag

Giuseppe Micieli

Simona Marcheselli

Piera Angela Tosi

Directory of Open Access Journals

Vascular Health and Risk Management

Safety and efficacy of alteplase in the treatment of acute ischemic stroke

Acute basilar thrombosis: angiologic-clinical comparison and therapeutic implications. Acta Radiol Suppl.

Acute stroke care in the US: results from the 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry.

Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.

Alteplase for acute stroke revisited: the first 10 years. Lancet Neurol.

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Basilar artery occlusion: clinical and radiological correlation.

Blood glucose, glycosylated haemoglobin, and outcome of ischemic brain infarction.

Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study.

Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury.

Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar hemorrhage in the elderly.

Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial.

Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke.

Clinical and imaging predictors of intracerebral hemorrhage in stroke patients treated with intravenous tissue plasminogen activator.

Clinical features of proven basilar artery occlusion.

Clinical importance of microbleeds in patients receiving IV thrombolysis.

Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.

Combined intravenous and intraarterial recombinant tissue plasminogen activator in acute ischemic stroke.

Combined intravenous and intraarterial versus intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke patients: Propensity score analysis [abstract].

Community-based thrombolytic therapy of acute ischemic stroke in Helsinki.

Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.

Computed tomographic findings in patients undergoing intra-arterial thrombolysis for acute ischemic stroke due to middle cerebral artery occlusion: results from the PROACT II trial.

del Zoppo GJ. Intraarterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar disease.

Diabetes and stress hyperglycaemia in stroke.

Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis. A study in 157 cases.

Early intravenous thrombolysis for acute ischemic stroke in a community-based approach.

Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator.

Early major ischemic changes on computed tomography should preclude use of tissue plasminogen activator.

Early stroke treatment associated with better outcome:

ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Effects of matrix metalloproteinase-9 gene knockout on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia.

Effects of tissue plasminogen activator for acute ischemic stroke at one year.

Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes.

Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci.

Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies.

Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.

Findings from the reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial.

Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association.

Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study.

Hemorrhagic transformation of cerebral infarction: possible mechanisms. Thromb Haemost.

Hemorrhagic transformation of ischemic brain tissue. Asymptomatic or symptomatic? Stroke.

Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort.

Hyperglycemia in the acute phase of stroke is not caused by stress.

Hyperglycemia is a stress response in acute stroke.

Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter study.

Intra-arterial and combined intravenous and intra-arterial thrombolytic therapy for distal carotid artery occlusion.

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up.

Intraarterial thrombolysis in vertebrobasilar occlusion.

Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke.

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke.

Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience.

Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety and efficacy in the first year of clinical practice.

Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.

Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.

Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.

Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study.

Is tissue-type plasminogen activator a neuromodulator? Mol Cell Neurosci.

Ischemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke.

Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke.

Local intraarterial fibrinolysis in acute vertebrobasilar occlusion. Technical developments and recent results.

Local intraarterial fibrinolysis in the carotid territory.

Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator for acute ischemic stroke in clinical practice: the Multicenter rt-PA Acute Stroke Survey.

Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment.

Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Inhibition of matrix metalloproteinase-9 reduces infarct size.

Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.

Matrix metalloproteinases and TIMPS are associated with blood brain barrier opening after reperfusion in rat brain.

Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.

MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia. Neurol Res.

MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol.

Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging.

Multivariable analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke.

Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group.

Number needed to treat estimates incorporating effects over the whole range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol.

Occlusion of the basilar artery: a clinical and pathological study.

Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke. A gradient-echo T2*-weighted brain MRI study.

Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (or =80 years) stroke patients.

Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients. Comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials.

Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.

Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke.

Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke.

Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy.

Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.

PROACT: A phase II randomized trial of recombinant prourokinase by direct arterial delivery in acute middle cerebral artery stroke; PROACT investigators, prolyse in acute cerebral thromboembolism.

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).

Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial.

Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med.

Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.

Shift analysis versus dichotomization of the modified Rankin scale outcome scores

SITS investigators. Thrombolysis with alteplase 3–4.5 h after acute ischemic stroke (SITS-ISTR): an observational study.

Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview.

Stroke in patients with diabetes.

Stroke thrombolysis: slow progress. Circulation.

Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis.

The etiology of posterior circulation infarcts: a prospective study using magnetic resonance imaging and magnetic resonance angiography.

The European Stroke Initiative Executive Committee and European Stroke Initiative Writing Group. European stroke initiative recommendations for stroke management—update 2003. Cerebrovasc Dis.

The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The interventional management of stroke study.

The influence of baseline prognostic variables on outcome after thrombolysis. MASTItaly Collaborative group.

The proteolytic activity of tissueplasminogen activator enhances NMDA receptor-mediated signaling. Nat Med.

The rt-PA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study.

http://doaj.org/search?source=%7B%22query%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22term%22%3A%7B%22id%22%3A%2240034da52bec41689ccab5017c74693d%22%7D%7D%5D%7D%7D%7D

Safety and efficacy of alteplase in the treatment of acute ischemic stroke

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals